FDA Ponders Drug Pricing In Opioid Abuse Analysis
This article was originally published in The Pink Sheet Daily
The agency, of course, cannot consider drug pricing in approval decisions, but is making itself aware as it mulls broader policy changes.
You may also be interested in...
US FDA estimates mandating naloxone co-prescriptions could dramatically increase spending to more than total estimated cost of opioid crisis itself; joint advisory committee to consider options to increase naloxone availability.
Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.
CVS in 31 states offers naloxone from pharmacists without a prescription and Walgreens offers it in 14, with plans to more than double the program this year. Whether from pharmacists or OTC, "an affordable price is essential if this is to reach the people who need it," says harm reduction advocate Scott Burris.